Lexeo Acquires Stelios to Expands its Gene Therapy Pipeline for Rare Cardiovascular Diseases
Shots:
- Lexeo acquires exclusive rights to three preclinical AAV-mediated gene therapy programs for the treatment of rare cardiac disorders- focused on TNNI3-associated HCM & ARVC
- The acquisition will complement and bolster LEXEO’s advanced pre-clinical gene therapy pipeline with the addition of three novel programs for rare cardiac diseases
- Additionally- preclinical results from the TNNI3-associated HCM gene therapy program showed compelling expression of the human TNNI3 gene in the heart in mouse models & two ARVC gene therapy programs demonstrated delivery of the gene that codes for Cx43 & PKP2
| Ref: Globe Newswire | Image: Yahoo Finance
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com